^
BIOMARKER:

PTPRD mutation

i
Other names: Protein-Tyrosine Phosphatase Delta, Rceptor-Type Tyrosine-Protein Phosphatase Delta, Protein Tyrosine Phosphatase, Receptor Type, Delta Polypeptide, R-PTP-Delta, Receptor-Type Tyrosine-Protein Phosphatase Delta, PTPRD, Protein Tyrosine Phosphatase Receptor Type D
Entrez ID:
Related biomarkers:
7d
Tissue or ctDNA PTPRD phosphatase domain deleterious mutations might function as a both prognostic and predictive biomarker predicting clinical outcomes of ICIs in ns-NSCLC patients, independent on TMB or PD-L1 expression.
Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
|
TMB (Tumor Mutational Burden) • PTPRD (Protein tyrosine phosphatase receptor type D)
|
PD-L1 expression • PTPRD mutation
2ms
These results explain PSGTs harbor distinct driver features of MAML2 or MYB rearrangement, accompanied with wide mutational diversity with very low rate of somatic mutation. Several important pathways, including the NOTCH and PI3K pathways, and chromatin remodeling could be targeted to improve the survival in patients with ACC.
Journal • Next-generation sequencing • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • FGFR1 (Fibroblast growth factor receptor 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • ASXL1 (ASXL Transcriptional Regulator 1) • PD-1 (Programmed cell death 1) • FLT1 (Fms-related tyrosine kinase 1) • KMT2A (Lysine Methyltransferase 2A) • RBM10 (RNA Binding Motif Protein 10) • PTPRD (Protein tyrosine phosphatase receptor type D) • INPP4B (Inositol polyphosphate-4-phosphatase type II B) • FOXP1 • CCND2 (Cyclin D2) • NOTCH4 (Notch 4) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
HRAS mutation • ASXL1 mutation • FGFR1 mutation • PTPRD mutation
4ms
This work suggested that PTPRD/PTPRT mutation might be a potential positive predictor for ICBs in NSCLC. These results need to be further confirmed in future.
Clinical • Clinical data • Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • JAK1 (Janus Kinase 1) • PTPRT (Protein tyrosine phosphatase receptor type T) • STAT1 (Signal Transducer And Activator Of Transcription 1)
|
PTPRD mutation • PTPRT mutation
6ms
Clinical • Journal
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • KMT2D (Lysine Methyltransferase 2D) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • PTPRD (Protein tyrosine phosphatase receptor type D) • EP300 (E1A binding protein p300) • WRN (WRN RecQ Like Helicase) • ALDH2 (Aldehyde Dehydrogenase 2 Family Member)
|
TP53 mutation • PTPRD mutation
10ms
TP53, KEAP1, NTRK3 and PTPRD gene accompanied may have less correlation with FLT3 mutation in NSCLC patients. Analysis of FLT3 mutations shows promise as a way to refine individual patients with NSCLC, and provides more insight into effective treatment strategies for patients with FLT3 mutations.
Clinical
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • KEAP1 (Kelch Like ECH Associated Protein 1) • PTPRD (Protein tyrosine phosphatase receptor type D)
|
TP53 mutation • FLT3 mutation • KEAP1 mutation • PTPRD mutation
over1year
Our results suggest that PTPRD/PTPRT mutation is associated with better PFS and OS in NSCLC patients receiving ICIs by increasing immune-related gene signatures. The role of PTPRD/PTPRT in immunotherapy is needed to be further studied. Research Funding: None
Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • PTPRT (Protein tyrosine phosphatase receptor type T)
|
PTPRD mutation